Next Article in Journal
Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways
Next Article in Special Issue
Comprehensive Metabolic Profiling of Euphorbiasteroid in Rats by Integrating UPLC-Q/TOF-MS and NMR as Well as Microbial Biotransformation
Previous Article in Journal
Effect of Expression of Nuclear-Encoded Cytochrome C Oxidase Subunit 4 Isoforms on Metabolic Profiles of Glioma Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Metabolites
Volume 12
Issue 8
10.3390/metabo12080752
metabolites-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Metabolite Identification of HIV-1 Capsid Modulators PF74 and 11L in Human Liver Microsomes

by
Shujing Xu
,
Lin Sun
,
Dang Ding
,
Xujie Zhang
,
Xinyong Liu
* and
Peng Zhan
*
Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China
*
Authors to whom correspondence should be addressed.
Metabolites 2022, 12(8), 752; https://doi.org/10.3390/metabo12080752
Submission received: 10 July 2022 / Revised: 10 August 2022 / Accepted: 11 August 2022 / Published: 16 August 2022
(This article belongs to the Special Issue Drug Discovery Metabolism and Biotransformation)
Browse Figures
Versions Notes

Abstract

:
PF74 and 11L, as potent modulators of the HIV-1 capsid protein, have been demonstrated to act at both early and late stages in the HIV-1 life cycle. However, their clearance is high in human liver microsomes (HLMs). The main goal of this study was to clarify the metabolism of PF74 and 11L in HLMs, and provide guidance for future structural optimization. To accomplish this, the phase-I metabolites of PF74 and 11L, resulting from in vitro incubation with HLMs, were investigated via ultra-performance liquid chromatography–ultraviolet–high-resolution mass spectrometry (UPLC–UV–HRMS). The results show that 17 phase-I metabolites were putatively annotated for PF74, whereas 16 phase-I metabolites were found for 11L. The main metabolic pathways of PF74 in HLMs were oxidation and demethylation, and the secondary metabolic pathway was hydrolysis; thus, the di-oxidation and demethylation products (M7, M9, M11, and M14) were found to be major metabolites of PF74 in HLMs. In comparison, the main metabolic pathways of 11L in HLMs were oxidation, demethylation, dehydrogenation, and oxidative deamination, with M6′, M11′, M15′, and M16′ as the main metabolites. We suggest that the indole ring and N-methyl group of PF74, and the aniline group, benzene ring R1′, N-methyl, and methoxy group of 11L, were the main metabolic soft spots. Therefore, our research illuminates structural optimization options in seeking improved HIV-1 CA modulators.

Graphical Abstract

1. Introduction

Human immunodeficiency virus type 1 (HIV-1) remains a worldwide healthcare concern despite the effective development of combination antiretroviral therapy (cART) [1,2]. Existing cART is projected to last a lifetime, and the virus will ultimately choose variants that are resistant to current treatment classes [3,4]. This necessitates the development of innovative medications with diverse resistance profiles and new targets. The multifunctional HIV-1 capsid protein (CA) represents an emerging and highly appealing target in HIV-1 medication research. CA plays essential roles in multiple events during viral replication, such as reverse transcription, nuclear entry, integration site distribution, assembly, and maturation [5,6,7]. Therefore, CA-targeting small molecules could provide antiviral characteristics in both the early and late stages. By far, the most intriguing CA-targeting compound is PF74; however, further clinical development of PF74 is mainly impeded by its inferior metabolic stability [8,9]. Additionally, our previous efforts involved replacing the indole moiety with benzenesulfonamide moiety, and we obtained compound 11L with increased antiviral activity, but only modestly better microsomal stability [10] (Figure 1). PF74 and 11L could affect the morphology and assembly process of viral particles through multiple effects to achieve the purpose of inhibiting viral replication, providing low stoichiometric loading advantages [10,11]. Theoretically, a small molecule could regulate unlimited capsids, which requires CA-targeting modulators with high metabolic stability. Therefore, determining their metabolic soft spots would be essential for directing the optimization process to enhance their pharmacokinetic features.
Metabolite profiling studies of new chemical entities (NCEs) are commonly performed in the pharmaceutical industry to aid in medication development [12,13]. These investigations not only provide information regarding the metabolic fate of NCEs, they also assist in the identification of metabolic soft spots in the parent molecule [14]. Elucidating the metabolic profile may allow for metabolic fortification during drug development efforts, and it is also significant for assessing overall drug safety and efficacy [15,16]. Ultra-performance liquid chromatography–ultraviolet–high-resolution mass spectrometry (UPLC–UV–HRMS) is a vital and effective method for the research of drug metabolism and pharmacokinetics, and it is widely utilized to characterize the structural properties of NCEs and their metabolites [17,18,19,20]. UPLC has a powerful separation capacity, making it one of the most useful tools currently available for separating complicated components [21,22,23]. The relative content of different metabolites can be determined according to the peak area of UV, which is helpful to preliminarily determine the main metabolites [18]. HRMS possesses the qualities of high speed, sensitivity, and selectivity, and it has been extensively employed for online structural analysis and quantitative detection of the components [22,24].
In this study, we investigated the phase-I metabolites and metabolic pathways of PF74 and 11L in human liver microsomes (HLMs). PF74 and 11L were incubated in the coexistence system of HLMs and NADPH for 60 min at 37 °C. The incubated samples were evaluated by UPLC–UV–HRMS. The relative content of each metabolite was determined according to the UV peak area. The structures of the metabolites were elucidated based on their MS spectra, tandem MS (MS/MS) spectra, fragmentation patterns, and comparison of the primary and secondary mass spectrometry signals with the parent drug. Finally, the metabolic pathways of PF74 and 11L were proposed based on metabolite data. In the in vitro study, a positive control was used to monitor the incubation. As described in the Supplementary Materials, 7-ethoxycoumarin (7-EC, 10 μM) was utilized as a positive control for phase-I metabolism to assure that proper incubation conditions were maintained. De-ethylated metabolites were observed in the 7-EC positive control, indicating phase-I metabolic activity in liver microsome incubation system.

2. Materials and Methods

2.1. Chemicals and Reagents

PF74 (purity > 99%) was obtained from MedChemExpress (Shanghai, China), and the information for 11L (purity > 99%) is provided in Supplementary Materials. In addition, 7-EC (purity > 97%) was purchased from Shanghai Macklin Biochemical Co., Ltd. (Shanghai, China). Acetonitrile, formic acid, water, and ammonium formate were purchased from Fisher Scientific (Fair Lawn, NJ, USA). All of the solvents used in the incubation and chromatographic system were UPLC-grade. Human liver microsomes (batch number: 38295) were obtained from Corning Incorporated (Corning, New York, NY, USA). Nicotinamide adenine dinucleotide phosphate (NADPH), phosphate buffer saline (PBS), and MgCl2 were obtained from Shanghai Aladdin Biochemical Technology Co., Ltd. (Shanghai, China).

2.2. Sample Preparation

To examine phase-I metabolites in vitro, microsomal incubation was performed with 100 mM phosphate buffer saline (pH 7.4) containing PF74 or 11L (10 μM), HLM (1.0 mg/mL), NADPH (1.0 mM), and MgCl2 (3.0 mM), and the reaction volume was 400 μL. Furthermore, 7-EC (10 μM) was utilized as a positive control for phase-I metabolism to guarantee that proper incubation conditions were maintained. Incubation without samples was used as a blank control. After preincubation for 5 min at 37 °C, the reactions were started by adding NADPH. After incubation for 60 min at 37 °C, the reactions were quenched by adding 800 μL of acetonitrile solution containing 0.1% formic acid. Afterward, the supernatants were obtained under centrifugation at 13,000 rpm for 10 min, and were then dried under nitrogen gas and the residues redissolved in 200 μL water/acetonitrile solution (v:v = 10:3). Aliquots were taken at 0 and 60 min, then, the sample (10 μL) was injected into the UPLC–UV–HRMS system for metabolite profiling and identification.

2.3. Chromatographic and Mass Spectrometric Methods

2.3.1. Chromatographic and Mass Spectrometric Methods of PF74

The UPLC–UV–HRMS analysis was carried out using an ACQUITY UPLC system hyphenated to a Thermo Q-Exactive HF tandem mass spectrometer equipped with an electrospray ionization interface that operated in positive ion mode.
Chromatographic Method: The chromatography was performed on an ACQUITY UPLC HSS T3 column (2.1 × 100 mm, 1.8 µm; Waters Corporation, MA, USA) maintained at 40 °C. Automatic injector temperature maintained at 8 °C. The mobile phase, made up of water/acetonitrile (v:v = 95:5) solution containing 0.1% formic acid and 2 mM ammonium formate (A), and water/acetonitrile (v:v = 5:95) solution containing 0.1% formic acid and 2 mM ammonium formate (B), was delivered at a flow rate of 300 µL/min. The gradient procedures were optimized as follows: 2% B at 0–2 min, 2–45% B at 2–6 min, 45–75% B at 6–12 min, 75–90% B at 12–16 min, 90% B at 16–18 min, and finally, 2% B at 18–20 min. The injection volume was 10 μL. The UV detection was performed using a photodiode array detector, and wavelength scanned from 190 to ~500 nm.
Mass Spectrometric Method: The electrospray ionization source parameters were set as follows: capillary temperature, 375 °C; spray voltage, 3.5 kV; sheath gas flow rate, 40 L/h; auxiliary gas flow rate, 15 L/h; auxiliary gas heater temperature, 300 °C; S-Lens voltage, 55 V. The data were collected in the m/z range of 140–1400 Da (full mass scan) and 200–2000 Da (MS/MS scan) in centroid mode. The collision energy was 10/15 V. The mass resolutions for full mass scans and MS/MS scans were chosen to be above 60,000 and 15,000/30,000, respectively. Collision-induced dissociation (CID) was utilized to attain the MS/MS fragment of PF74 and its metabolites.

2.3.2. Chromatographic and Mass Spectrometric Methods of 11L

The UPLC–UV–HRMS analysis was carried out using an ACQUITY UPLC system hyphenated to a Thermo Q-Exactive HF tandem mass spectrometer equipped with an electrospray ionization interface that operated in positive or negative ion mode.
Chromatographic Method: The chromatography was performed on an ACQUITY UPLC HSS T3 column (2.1 × 100 mm, 1.8 µm; Waters Corporation, MA, USA) maintained at 40 °C. The automatic injector temperature was maintained at 8 °C. The mobile phase, made up of water/acetonitrile (v:v = 95:5) solution containing 0.1% formic acid and 2 mM ammonium formate (A), and water/acetonitrile (v:v = 5:95) solution containing 0.1% formic acid and 2 mM ammonium formate (B), was delivered at a flow rate of 500 µL/min. The gradient procedures were optimized as follows: 2% B at 0–2 min, 2–55% B at 2–12 min, 55–90% B at 12–16 min, 90% B at 16–18 min, and finally, 2% B at 18–20 min. The injection volume was 10 μL. UV detection was performed using a photodiode array detector, and wavelength scanned from 190 to ~500 nm.
Mass Spectrometric Method: The electrospray ionization source parameters were set as follows: capillary temperature, 375 °C; spray voltage, 3.5 kV (+), 3.0 kV (−); sheath gas flow rate, 40 L/h; auxiliary gas flow rate, 15 L/h; auxiliary gas heater temperature, 300 °C; S-Lens voltage, 55 V. The data were collected in the m/z range of 140–1400 Da (+, full mass scan), 120–1400 (−, full mass scan), and 200–2000 Da (MS/MS scan) in centroid mode. The collision energy was 10/15/20 V (+), 10/20/30 V (−). The mass resolutions for full mass scans and MS/MS scans were chosen to be above 60,000 and 15,000, respectively. Collision-induced dissociation (CID) was utilized to attain the MS/MS fragment of 11L and its metabolites.

2.4. Data Processing

The acquired data sets were captured and analyzed by Thermo Xcaliber 4.2 workstation (Thermo Scientific, Bremen, Germany). The possible element composition was speculated by accurate molecular mass, and the data were processed by mass spectrometry fragmentation information. The molecular formulae of parent ions and fragment ions were predicted using a molecular formula prediction module, and the structures of metabolites, in vitro, of PF74 and 11L were identified. The maximum mass errors between the measured and the theoretical value were limited to 5 ppm.

3. Results and Discussion

3.1. Identification of PF74 Metabolites and Proposed Metabolic Pathways in HLMs

Figure 2 displays the UPLC–UV chromatogram of PF74 in HLMs at the detection wavelength of 254–310 nm, and Figure 3 displays the extracted ion chromatogram (XIC) of PF74 in HLMs. Metabolites were tentatively identified by comparing the UPLC–UV and UPLC–HRMS spectra and retention times of potential metabolites to the parent compound PF74. It is worth noting that after incubation at 37 °C for 60 min, PF74 was almost completely metabolized in HLMs. A total of 17 phase-I metabolites were discovered in the HLMs, and their spectra were compared to PF74 for structural confirmation (Figure 2 and Figure 3). According to the UV peak area, M7, M9, M11, and M14 were preliminarily identified as the main metabolites (Figure 2 and Table 1).
The first step in identifying the structures of metabolites was to examine the MS/MS fragmentation pattern of PF74. The MS/MS fragmentation pattern of PF74 was studied in positive mode. A protonated molecular ion [M + H]+ of PF74 at m/z 426.2151 was found in the full-scan mass spectrum. The protonated molecules then produced a series of characteristic fragment ions at m/z 320.1472, 319.1440, 291.1489, 263.1539, 214.1732, 172.0762, 144.0806, 120.0811 and 57.5965. PF74 was eluted at 9.91 min under the experimental conditions. The MS/MS product ion spectrum and predominant fragmentation patterns of PF74 were depicted in Figure 4.

3.1.1. Metabolite Profiling of PF74 in HLMs

A list of all the putative metabolites of PF74 with the proposed type of biotransformation and elemental composition, as well as the retention time, relative abundance, UV peak area, accurate mass of the protonated molecule and mass error, were summarized in Table 1 and Table 2. UPLC–MS/MS analysis of unchanged PF74 and its 17 metabolites yielded informative and prominent product ions for structural characterization (Figure S2).

Amide Hydrolysis Metabolite (M1)

M1, eluted at 5.85 min, gave rise to its [M + H]+ ion at m/z 255.1490 (C18N6H12O). It was 171 u lower than that of PF74, and produced secondary fragment ions at m/z 120.08, indicating that it might be the amide bond adjacent to the indole ring hydrolyzed to the amino (−171 u) product (Figure S2A).

Tri-oxidation and Demethylation Metabolites (M2, M3, M6, M8, M10, and M12)

Metabolites M2, M3, M6, M8, M10, and M12 exhibited retention times at 6.57, 6.61, 7.05, 7.29, 7.40, and 7.65 min, respectively, and they displayed the same theoretical protonated ion [M + H]+ at m/z 460.1867 (C26H25N3O5). This is 34u higher than PF74, indicating that they might be tri-oxidation (+48 u) and N-demethylation (−14 u) products. Metabolites M2, M3, M6, M8, and M10 lost one molecule of water to form secondary fragment ions at m/z 442.18. Metabolites M2, M3, and M10 had secondary fragment ions at m/z 204.07, 186.05, and 162.05, suggesting that the indole ring was oxidized. Among them, M2 and M10 had secondary fragment ions at m/z 351.13, 323.14, 190.09, and 120.08, indicating that benzene ring R2 did not undergo oxidation. In accordance with the secondary fragment ion at m/z 257.13, it is speculated that benzene ring R1 underwent mono-oxidation and N-demethylation (Figure S2B,J). Additionally, the secondary fragment ions at m/z 206.08 and 136.08 of M3 suggest that the mono-oxidation of benzene ring R2 had occurred (Figure S2C). Metabolite M6 had secondary fragment ions at m/z 188.07 and 170.06, indicating that the indole ring was mono-oxidized, and the secondary fragment ions at m/z 367.13, 339.13, 222.08, and 152.07 indicate that the benzene ring R2 was di-oxidized (Figure S2F). Secondary fragment ions at m/z 202.05 and 186.05 suggest that the indole ring of metabolite M8 underwent oxidation (Figure S2H). In accordance with the secondary fragment ions at m/z 367.13 and 339.13 of M12, the oxidation of the indole ring and benzene ring R2 is also speculated (Figure S2L).

Tri-oxidation Metabolites (M4 and M5)

Metabolites M4 and M5 possessed the same theoretical protonated molecular ion [M + H]+ at m/z 474.2024 (C27H27N3O5), and were detected at 6.68 and 7.05 min, respectively. They were 48 u higher than that of PF74; therefore, they could be the tri-oxidation products. The secondary fragment ion at m/z 456.19 was formed when they lost one molecule of water. The metabolite M4 had secondary fragment ions at m/z 188.07 and 170.06, demonstrating that the indole ring was mono-oxidized. The secondary fragment ions at m/z 222.08 and 152.07 show that the benzene ring R2 was di-oxidized, and m/z 108.08 show that the benzene ring R1 was not oxidized (Figure S2D). The secondary fragment ions at m/z 202.05 and 174.06 in the metabolite M5 indicate that the indole ring was tri-oxidized, and the secondary fragment ions at m/z 120.08 and 108.08 indicate that the benzene rings R1 and R2 were not oxidized (Figure S2E).

Di-oxidation and Demethylation Metabolites (M7, M11, M13, M14, and M16)

Metabolites M7, M11, M13, M14, and M16, with their retention times of 7.11, 7.56, 7.65, 7.79, and 8.90 min, respectively, were 18 u higher than that of PF74. They displayed the same theoretical protonated molecular ion [M + H]+ at m/z 444.1918 (C26H25N3O4), which indicates that they were di-oxidation (+32 u) and demethylation (−14 u) products. The metabolites M7 and M13 had secondary fragment ions at m/z 188.07 and 170.06, Implying that the indole ring was mono-oxidized. Secondary fragment ions at m/z 120.08 indicate that benzene ring R2 was not oxidized, while secondary fragment ions at m/z 257.13 suggest that benzene ring R1 was mono-oxidized and N-demethylated (Figure S2G,M). The metabolites M11, M14, and M16 had secondary fragment ions at m/z 204.07, 186.06, and 162.06, and we speculate that the indole ring was di-oxidized (Figure S2K,N,P).

Di-oxidation Metabolite (M9)

Metabolite M9, eluted at 7.40 min, possessed the experimental [M + H]+ ion at m/z 458.2074 (C27H27N3O4), which was 32 u higher than that of PF74, meaning that it might be a di-oxidation (+32 u) product of PF74. Secondary fragment ions at m/z 204.07 and 162.05 indicate that the indole ring was oxidized, and m/z 190.09 and 108.08 indicate that the benzene rings R1 and R2 were not oxidized. Additionally, m/z 440.20, 333.12, and 305.13 were a series of fragments formed by oxidative dehydration (Figure S2I).

Mono-oxidation Metabolite (M15)

Metabolite M15 with a protonated ion [M + H]+ at m/z 442.2134 (C27H27N3O3), was eluted at 8.75 min. It was 16 u higher than that of PF74, showing that there was a mono-oxidation product. The secondary fragment ion at m/z 188.07 determines that the indole ring was mono-oxidized, and m/z 424.20, 317.13, 289.13, and 170.06 were a series of fragments formed by oxidative dehydration (Figure S2O).

Mono-oxidation and Demethylation Metabolite (M17)

Metabolite M17, 2 u higher than that of PF74, possessed a protonated molecule ion [M + H]+ at m/z 428.1969 (C26H25N3O3) with the retention time of 9.37 min, suggesting that M17 was the product of mono-oxidation (+16 u) and demethylation (−14 u). In addition, m/z 188.07 leads us to speculate that the indole ring was mono-oxidized, and m/z 410.19, 317.18, 289.13, and 170.06 were a series of fragments formed by oxidative dehydration (Figure S2Q).

3.1.2. Proposed Metabolic Pathways of PF74

In this investigation, a total of 17 metabolites were found in HLMs of PF74. The proposed metabolic pathways of PF74 are exhibited in Figure 5. There was a series of metabolic reactions containing mono-oxidation, di-oxidation, tri-oxidation, mono-oxidation and demethylation, di-oxidation and demethylation, tri-oxidation and demethylation, amide hydrolysis, and so on. Metabolites M7, M11, M14 (di-oxidation and N-demethylation products), and M9 (di-oxidation product) were the four most abundant metabolites, so the main metabolic pathways of PF74 in HLMs were di-oxidation and N-demethylation, which also suggests that the indole ring, benzene ring R1, and N-methyl group were the main metabolic soft spots. In a previous study by Wang et al. [25], upon substituting the electron-rich indole ring of PF74 with a less electron-rich benzamide group, a preferred compound with similar submicromolar potency and much longer (51-fold) half-life was reported. Additionally, by replacing the benzene ring R1 with the electron-deficient benzothiazole moiety, we found a compound that exhibited markedly improved metabolic stability in HLMs, with a half-life 109-fold that of PF74 [26]. Furthermore, Sahani et al. [27] reported a PF74-like analog with 39 times enhanced metabolic stability over PF74, which led to increased resistance to N-methylation conceived via building the phenylalanine carboxamide into a pyridine ring. These results are consistent with our current findings, wherein we have identified the phase-I oxidative and N-demethylated metabolites as major metabolites of PF74 in HLMs.

3.2. Identification of 11L Metabolites and Proposed Metabolic Pathways in HLMs

Figure 6 shows the UPLC–UV chromatogram of 11L in HLMs at the detection wavelength of 240–320 nm, and Figure 7 show the XIC of 11L in HLMs. Metabolites were tentatively identified by comparing the UPLC–UV and UPLC–HRMS spectra and retention times of potential metabolites to the parent compound 11L. After incubation at 37 °C for 60 min, the relative abundance of 11L in HLMs was 7.11%, which explains why 11L (t1/2 = 4.1 min) had a slightly longer half-life than PF74 (t1/2 = 1.3 min). A total of 16 metabolites were discovered in HLMs, and their spectra were compared with those of 11L for structural confirmation (Figure 7 and Figure 8). According to the UV peak area, M6′, M11′, M15′, and M16′ are preliminarily identified as the main metabolites (Figure 6 and Table 3).
The first step in identifying the structures of metabolites was to examine the MS/MS fragmentation pattern of parent compound 11L. The MS/MS fragmentation pattern of 11L was examined in positive and negative mode. A protonated molecular ion [M + H]+ of 11L at m/z 580.2224 and a deprotonated molecular ion [M − H]− of 11L at m/z 578.2077 were observed in the full-scan mass spectrum. The protonated molecules then produced a series of characteristic fragment ions at m/z 443.1383, 415.1433, 296.0697, 268.0749, 240.0791, 211.5220, and 138.0914, and the deprotonated molecules then produced a series of characteristic fragment ions at m/z 441.1228, 417.1234, 311.0818, 294.0552, 254.0602, 228.0443, 186.0554, 156.0116, and 92.0495. Moreover, 11L was eluted at 10.69 min under the experimental conditions. The MS/MS product ion spectrum and predominant fragmentation patterns of 11L are displayed in Figure 8.

3.2.1. Metabolite Profiling of 11L in HLMs

A list of all the putative metabolites of 11L with the proposed type of biotransformation and elemental composition, as well as the retention time, relative abundance, UV peak area, accurate mass of the protonated (or deprotonated) molecule, and mass error, are summarized in Table 3 and Table 4. UPLC–MS/MS analysis of unchanged 11L and its 16 metabolites yielded informative and prominent product ions for structural characterization (Figure S3).

Tri-oxidation Metabolite (M1′)

Metabolite M1′, eluted at 8.29 min, possessed the experimental protonated molecular ion [M + H]+ at m/z 628.2078 (C29H33N5O9S), which was 48 u higher than that of 11L, meaning that it might be a tri-oxidation (+48 u) product of 11L. The secondary fragment ion at m/z 284.07 suggests that the benzene ring R1′ had not been oxidized, whereas m/z 138.09 is evidence of the di-oxidation of benzene ring R2′ (Figure S3A).

Di-oxidation Metabolites (M2′, M6′, M13′)

Metabolites M2′ and M6′ were observed at retention times of 8.49 and 8.82 min, respectively, with the same experimental protonated molecular ion [M + H]+ at m/z 612.2123 (C29H33N5O8S). The two metabolites were 32 u higher than 11L, suggesting they were the di-oxidation products. The secondary fragment ions at m/z 268.08 and 138.09 of the metabolite M2′ indicate that benzenesulfonamide piperazinone and benzene ring R1′ did not undergo oxidation, and m/z 475.13 and 296.07 indicate that benzene ring R2′ underwent di-oxidation (Figure S3B). The secondary fragment ion at m/z 172.01 of metabolite M6′ demonstrates that aniline was mono-oxidized, and m/z 475.13 and 312.07 indicate that benzene ring R2′ was mono-oxidized (Figure S3F).
Furthermore, M13′ was detected at a retention time of 10.06 min with the experimental deprotonated ion [M − H]− at m/z 610.1976 (C29H33N5O8S), which was 32 u higher than that of 11L, meaning that it might be a di-oxidation (+32 u) product of 11L. The secondary fragment ion at m/z 172.01 of metabolite M13′ shows that aniline was mono-oxidized, and m/z 270.06 and 172.01 show that piperazinone was mono-oxidized (Figure S3M).

Demethylation and Mono-oxidation Metabolites (M3′, M9′, M10′, M11′)

Metabolites M3′ and M11′ produced the same theoretical protonated ions [M + H]+ at m/z 582.2017 (C28H31N5O7S), which were eluted at 8.56 min and 9.98 min, respectively. They were 2 u higher than 11L, and we speculate that metabolites M3′ and M11′ were demethylation (−14 u) and mono-oxidation (+16 u) products. The secondary fragment ion at m/z 140.07 of M3′ indicates that benzene ring R1′ was mono-oxidized and demethylated, and m/z 268.08, 296.07, and 443.14 indicate that benzene sulfonamide piperazinone and benzene ring R2′ were not oxidized (Figure S3C). The secondary fragment ion at m/z 172.01 of M11′ implies the mono-oxidation of aniline, and m/z 122.06 indicates oxidative demethylation (Figure S3K).
Moreover, M9′ and M10′, with their retention times of 9.78 and 9.83 min, respectively, were 2 u higher than that of 11L. They displayed the same theoretical deprotonated ion [M − H]− at m/z 580.1871 (C28H31N5O7S), which indicates that they were demethylation (−14 u) and mono-oxidation (+16 u) products. The secondary fragment ion at m/z 156.01 suggests that aniline was not oxidized (Figure S3I,J).

Demethylation and Di-oxidation Metabolite (M4′)

Metabolite M4′, 18u higher than that of 11L, presented an experimental protonated ion [M + H]+ at m/z 598.1962 (C28H31N5O8S) with the retention time of 8.60 min, which indicates that it was the product of demethylation (−14 u) and di-oxidation (+32 u). The secondary fragment ion at m/z 172.01 shows that aniline was mono-oxidized, whereas m/z 475.13 and 312.07 show that the benzene ring R2′ was mono-oxidized, and m/z 122.06 suggests oxygen demethylation (Figure S3D).

N-demethylation and O-demethylation Metabolite (M5′)

Metabolite M5′ was eluted at 8.79 min with an experimental protonated ion [M + H]+ at m/z 552.1917 (C27H29N5O6S). It was 28u lower than that of 11L, showing that was a product of N-demethylation (−14 u) and O-demethylation (−14 u). The secondary fragment ions at m/z 443.14, 296.07 and 268.08 indicate that only the demethylation reaction occurred in M5′ (Figure S3E).

Mono-oxidation Metabolites (M7′, M16′)

Metabolites M7′ and M16′ were detected at 9.05 and 10.36 min, and possessed the same theoretical protonated ions [M + H]+ at m/z 596.2174 (C29H33N5O7S), which were 16 u higher than that of 11L, and we speculate that metabolites M7′ and M16′ were mono-oxidized (+16 u) products. The secondary fragment ions at m/z 268.08 and 138.09 of M7′ indicate that benzenesulfonamide piperazinone and benzene ring R1′ were not oxidized, and m/z 459.13 and 296.07 indicate that benzene ring R2′ was mono-oxidized (Figure S3G). The m/z 312.07 and 284.07 of M16′ indicate the mono-oxidation of benzenesulfonamide piperazinone (Figure S3P).

N-demethylation Metabolite (M8′)

Metabolite M8′, possessing an experimental protonated ion [M + H]+ at m/z 566.2041 (C28H31N5O6S), was eluted at 9.08 min, which was 14 u higher than 11L. Due to the secondary fragment ions at m/z 124.08, M8′ is presumed to be the product of N-demethylation (−14 u) (Figure S3H).

Dehydrogenation and Mono-oxidation Metabolite (M12′)

Metabolite M12′, eluted at 10.04 min, possessed the experimental protonated ion [M + H]+ at m/z 594.2021 (C29H31N5O7S), which was 14 u higher than that of 11L, meaning that it might be a dehydrogenated (−2 u) and mono-oxidized (+16 u) product. The secondary fragment ion at m/z 172.01 of M12′ indicates the mono-oxidation of aniline, and m/z 254.06 and 172.01 indicate the reductive dehydrogenation of piperazinone (Figure S3L).

Demethylation Metabolite (M14′)

Metabolite M14′, 14 u lower than that of 11L, presented an experimental protonated ion [M + H]+ at m/z 566.2068 (C28H31N5O6S) with the retention time of 10.29 min, suggesting that M14′ was the product of demethylation (−14 u). The secondary fragment ions at m/z 443.14, 296.07, 268.08, and 156.01 indicate that only the demethylation reaction occurred in M14′ (Figure S3N).

Oxidative Deamination and Mono-oxidation Metabolite (M15′)

Metabolite M15′ was eluted at 10.32 min with an experimental protonated ion [M + H]+ at m/z 597.2002 (C29H32N4O8S). It was 17u higher than that of 11L, showing that it was a product of oxidative deamination (+16 u and −15 u) and mono-oxidation (+16 u). The m/z 313.05 and 285.05 indicate that mono-oxidation and oxidative deamination of benzenesulfonamide piperazinone. The m/z 579.21 was the secondary fragment ion obtained by oxidative dehydration (Figure S3O).

3.2.2. Proposed Metabolic Pathways of 11L

On the basis of the MS/MS spectra and fragmentation patterns, the metabolic pathways of 11L are accordingly proposed, as shown in Figure 9. The metabolic reactions are summarized as follows: mono-oxidation, di-oxidation, tri-oxidation, demethylation, mono-oxidation and demethylation, mono-oxidation and oxidative deamination, mono-oxidation and dehydrogenation, N- demethylation and O-demethylation. Metabolite M6′ (di-oxidation product), M11′ (mono-oxidation and demethylation product), M15′ (mono-oxidation and oxidative deamination product), and M16′ (mono-oxidation product) were the four metabolites with the highest relative abundance. Therefore, oxidation, demethylation, and oxidative deamination were the main metabolic pathways of 11L in HLMs, which also indicates that the aniline group, benzene ring R1′, N-methyl, and methoxy group of 11L were the main metabolic soft spots. It has been reported that the introduction of chlorine and fluorine atoms can block metabolically labile sites and improve the metabolic stability of compounds [28]. Recently, Sahani et al. [29] found that the substitution of a methoxy group on benzene ring R1′ and an amino group on aniline via chlorine atoms could slightly improve the metabolic stability of 11L-like analogs. Notably, lenacapavir, a long-acting capsid modulator currently in clinical phase III, contains a core structure similar to PF74 and 11L [30]. However, its left wing introduced a fluorine-rich tetrahydrocyclopenta-pyrazole ring, and replaced the benzene ring R1 (R1′) with an indazole ring, as well as introducing the pyridine group to avoid N-methylation [31]. The incorporation of electron-withdrawing groups (halogens and sulfonyls), metabolically stable ring systems (cyclopentane and pyrazoles), and rigidifying elements might be the reasons for its high metabolic stability.

4. Conclusions

The primary goal of metabolite screening in early drug development is to detect metabolic soft spots that result in poor metabolic stability. This information can direct synthetic chemistry efforts through the identification of compounds with desirable pharmacokinetic characteristics. In this study, phase-I metabolites, and possible metabolic pathways of PF74 and 11L in HLMs, were identified for the first time. According to the ionization and fragmentation rules of ESI-MS, the metabolites were identified by UPLC–UV–HRMS data based on the characteristic fragments and characteristic neutral loss of PF74 and 11L. For PF74, the oxidation of the indole ring and N-demethylation of the parent compound were the main transformations. For 11L, oxidation of the aniline group and benzene ring R1′, demethylation, dehydrogenation, and oxidative deamination metabolites were the relatively most intense. Therefore, it may be an effective method to improve the metabolic stability of compounds by substituting electron-deficient groups for electron-rich indole ring and aniline groups, and substituting benzo-aromatic heterocyclic rings for benzo-methoxy groups to overcome the defects of oxidation and demethylation. In summary, this study’s findings of metabolic transformation information will open up prospects for structural optimization, leading to the identification of novel, more metabolically stable HIV-1 CA modulators.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/metabo12080752/s1, Scheme S1: The synthetic route of 11L. Table S1: Metabolic rate of 7-EC in HLMs (%). Figure S1: UPLC–UV chromatograms of 7-EC and its metabolites in HLMs (wavelength: 290–360 nm). Figure S2: Collision-induced dissociation (CID) spectra and proposed fragmentation patterns for metabolites of PF74. Figure S3: CID spectra and proposed fragmentation patterns for metabolites of 11L.

Author Contributions

Conceptualization, S.X. and L.S.; methodology, L.S.; investigation, S.X.; writing—original draft preparation, S.X.; writing—review and editing, D.D., X.Z. and P.Z.; supervision, S.X. and D.D.; project administration: P.Z.; funding acquisition, X.L. and P.Z. All authors have read and agreed to the published version of the manuscript.

Funding

National Natural Science Foundation of China (NSFC No. 82173677), and Science Foundation for Outstanding Young Scholars of Shandong Province (No. ZR2020JQ31).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Davenport, M.P.; Khoury, D.S.; Cromer, D.; Lewin, S.R.; Kelleher, A.D.; Kent, S.J. Functional cure of HIV: The scale of the challenge. Nat. Rev. Immunol. 2019, 19, 45–54. [Google Scholar] [CrossRef] [PubMed]
  2. Kleinpeter, A.B.; Freed, E.O. HIV-1 Maturation: Lessons Learned from Inhibitors. Viruses 2020, 12, 940. [Google Scholar] [CrossRef] [PubMed]
  3. Zhan, P.; Pannecouque, C.; De Clercq, E.; Liu, X. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. J. Med. Chem. 2016, 59, 2849–2878. [Google Scholar] [CrossRef] [PubMed]
  4. Maeda, K.; Das, D.; Kobayakawa, T.; Tamamura, H.; Takeuchi, H. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. Curr. Top. Med. Chem. 2019, 19, 1621–1649. [Google Scholar] [CrossRef]
  5. Xu, S.; Sun, L.; Huang, B.; Liu, X.; Zhan, P. Medicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment. Future Med. Chem. 2020, 12, 1281–1284. [Google Scholar] [CrossRef]
  6. Zhang, X.; Xu, S.; Sun, L.; Ding, D.; Tao, Y.; Kang, D.; Liu, X.; Zhan, P. HIV-1 capsid inhibitors: A sword to destroy the virus. Future Med. Chem. 2022, 14, 605–607. [Google Scholar] [CrossRef]
  7. Sun, L.; Zhang, X.; Xu, S.; Huang, T.; Song, S.; Cherukupalli, S.; Zhan, P.; Liu, X. An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors. Eur. J. Med. Chem. 2021, 217, 113380. [Google Scholar] [CrossRef]
  8. Shi, J.; Zhou, J.; Shah, V.B.; Aiken, C.; Whitby, K. Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabilization. J. Virol. 2011, 85, 542–549. [Google Scholar] [CrossRef]
  9. Balasubramaniam, M.; Zhou, J.; Addai, A.; Martinez, P.; Pandhare, J.; Aiken, C.; Dash, C. PF74 Inhibits HIV-1 Integration by Altering the Composition of the Preintegration Complex. J. Virol. 2019, 93, e01741-18. [Google Scholar] [CrossRef]
  10. Sun, L.; Dick, A.; Meuser, M.E.; Huang, T.; Zalloum, W.A.; Chen, C.H.; Cherukupalli, S.; Xu, S.; Ding, X.; Gao, P.; et al. Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. J. Med. Chem. 2020, 63, 4790–4810. [Google Scholar] [CrossRef]
  11. Pak, A.J.; Grime, J.M.A.; Yu, A.; Voth, G.A. Off-Pathway Assembly: A Broad-Spectrum Mechanism of Action for Drugs That Undermine Controlled HIV-1 Viral Capsid Formation. J. Am. Chem. Soc. 2019, 141, 10214–10224. [Google Scholar] [CrossRef] [PubMed]
  12. Baranczewski, P.; Stańczak, A.; Kautiainen, A.; Sandin, P.; Edlund, P.-O. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol. Rep. 2006, 58, 341. [Google Scholar] [PubMed]
  13. Słoczyńska, K.; Gunia-Krzyżak, A.; Koczurkiewicz, P.; Wójcik-Pszczoła, K.; Żelaszczyk, D.; Popiół, J.; Pękala, E. Metabolic stability and its role in the discovery of new chemical entities. Acta Pharm. 2019, 69, 345–361. [Google Scholar] [CrossRef] [PubMed]
  14. Trunzer, M.; Faller, B.; Zimmerlin, A. Metabolic Soft Spot Identification and Compound Optimization in Early Discovery Phases Using MetaSite and LC-MS/MS Validation. J. Med. Chem. 2009, 52, 329–335. [Google Scholar] [CrossRef] [PubMed]
  15. Padilha, E.C.; Shah, P.; Rai, G.; Xu, X. NOX2 inhibitor GSK2795039 metabolite identification towards drug optimization. J. Pharm. Biomed. Anal. 2021, 201, 114102. [Google Scholar] [CrossRef]
  16. Lee, K.; Lee, J.-Y.; Lee, K.; Jung, C.-R.; Kim, M.J.; Kim, J.A.; Yoo, D.G.; Shin, E.J.; Oh, S.J. Metabolite Profiling and Characterization of LW6, a Novel HIF-1α Inhibitor, as an Antitumor Drug Candidate in Mice. Molecules 2021, 26, 1951. [Google Scholar] [CrossRef]
  17. Wolfender, J.L.; Ndjoko, K.; Hostettmann, K. Liquid chromatography with ultraviolet absorbance-mass spectrometric detection and with nuclear magnetic resonance spectroscopy: A powerful combination for the on-line structural investigation of plant metabolites. J. Chromatogr. A 2003, 1000, 437–455. [Google Scholar] [CrossRef]
  18. Chen, Y.; Monshouwer, M.; Fitch, W.L. Analytical Tools and Approaches for Metabolite Identification in Early Drug Discovery. Pharm. Res. 2007, 24, 248–257. [Google Scholar] [CrossRef]
  19. Pérez-Victoria, I.; Martín, J.; Reyes, F. Combined LC/UV/MS and NMR Strategies for the Dereplication of Marine Natural Products. Planta. Med. 2016, 82, 857–871. [Google Scholar]
  20. Breindahl, T.; Evans-Brown, M.; Hindersson, P.; McVeigh, J.; Bellis, M.; Stensballe, A.; Kimergård, A. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test. Anal. 2015, 7, 164–172. [Google Scholar] [CrossRef]
  21. Liang, Y.; Zhao, W.; Wang, C.; Wang, Z.; Wang, Z.; Zhang, J. A Comprehensive Screening and Identification of Genistin Metabolites in Rats Based on Multiple Metabolite Templates Combined with UHPLC-HRMS Analysis. Molecules 2018, 23, 1862. [Google Scholar] [CrossRef] [PubMed]
  22. Paudel, S.; Kim, Y.; Choi, S.M.; Kim, J.; Bae, J.; Lee, T.; Lee, S. Identification of suberosin metabolites in human liver microsomes by high-performance liquid chromatography combined with high-resolution quadrupole–orbitrap mass spectrometer. Biol. Mass Spectrom. 2021, 56, e4623. [Google Scholar] [CrossRef] [PubMed]
  23. Zhou, X.; Li, L.; Deng, P.; Chen, X.; Zhong, D. Characterization of metabolites of GLS4 in humans using ultrahigh-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2013, 27, 2483–2492. [Google Scholar] [CrossRef]
  24. Montesano, C.; Vincenti, F.; Fanti, F.; Marti, M.; Bilel, S.; Togna, A.; Gregori, A.; Di Rosa, F.; Sergi, M. Untargeted Metabolic Profiling of 4-Fluoro-Furanylfentanyl and Isobutyrylfentanyl in Mouse Hepatocytes and Urine by Means of LC-HRMS. Metabolites 2021, 11, 97. [Google Scholar] [CrossRef]
  25. Wang, L.; Casey, M.C.; Vernekar, S.K.V.; Sahani, R.L.; Kirby, K.A.; Du, H.; Zhang, H.; Tedbury, P.R.; Xie, J.; Sarafianos, S.G.; et al. Novel PF74-like small molecules targeting the HIV-1 capsid protein: Balance of potency and metabolic stability. Acta Pharm. Sin. B 2021, 11, 810–822. [Google Scholar] [CrossRef] [PubMed]
  26. Xu, S.; Sun, L.; Dick, A.; Zalloum, W.A.; Huang, T.; Meuser, M.E.; Zhang, X.; Tao, Y.; Cherukupalli, S.; Ding, D.; et al. Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. Eur. J. Med. Chem. 2022, 227, 113903. [Google Scholar] [CrossRef] [PubMed]
  27. Sahani, R.; Diana-Rivero, R.; Vernekar, S.; Wang, L.; Du, H.; Zhang, H.; Castaner, A.; Casey, M.; Kirby, K.; Tedbury, P.; et al. Design, Synthesis and Characterization of HIV-1 CA-Targeting Small Molecules: Conformational Restriction of PF74. Viruses 2021, 13, 479. [Google Scholar] [CrossRef] [PubMed]
  28. Wang, J.; Sánchez-Roselló, M.; Aceña, J.L.; del Pozo, C.; Sorochinsky, A.E.; Fustero, S.; Soloshonok, V.A.; Liu, H. Fluorine in pharmaceutical industry: Fluorine-containing drugs introduced to the market in the last decade (2001–2011). Chem. Rev. 2014, 114, 2432–2506. [Google Scholar] [CrossRef]
  29. Sahani, R.L.; Akther, T.; Cilento, M.E.; Castaner, A.E.; Zhang, H.; Kirby, K.A.; Xie, J.; Sarafianos, S.G.; Wang, Z. Potency and metabolic stability: A molecular hybrid case in the design of novel PF74-like small molecules targeting HIV-1 capsid protein. RSC Med. Chem. 2021, 12, 2031–2044. [Google Scholar] [CrossRef]
  30. Bester, S.M.; Wei, G.; Zhao, H.; Adu-Ampratwum, D.; Iqbal, N.; Courouble, V.V.; Francis, A.C.; Annamalai, A.S.; Singh, P.K.; Shkriabai, N.; et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science 2020, 370, 360–364. [Google Scholar] [CrossRef]
  31. Link, J.O.; Rhee, M.S.; Tse, W.C.; Zheng, J.; Somoza, J.R.; Rowe, W.; Begley, R.; Chiu, A.; Mulato, A.; Hansen, D.; et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 2020, 584, 614–618. [Google Scholar] [CrossRef] [PubMed]
Metabolites 12 00752 g001 550
Figure 1. The chemical structures of PF74 and 11L [10]. EC50 is the concentration of the compound required to achieve 50% protection of TZM-bl cells against HIV-1-induced cytopathic effect, determined in at least triplicate against HIV-1 in TZM-bl cells; t1/2 is the half-life; and CLint is the intrinsic clearance.
Figure 1. The chemical structures of PF74 and 11L [10]. EC50 is the concentration of the compound required to achieve 50% protection of TZM-bl cells against HIV-1-induced cytopathic effect, determined in at least triplicate against HIV-1 in TZM-bl cells; t1/2 is the half-life; and CLint is the intrinsic clearance.
Metabolites 12 00752 g001
Metabolites 12 00752 g002 550
Figure 2. UPLC–UV (254–310 nm) chromategrams of PF74 in HLMs: (A) UPLC–UV spectrum of T60 (M1 and M15 are not listed due to weak UV absorption); (B) UPLC–UV spectrum of T0; (C) blank UPLC–UV spectrum.
Figure 2. UPLC–UV (254–310 nm) chromategrams of PF74 in HLMs: (A) UPLC–UV spectrum of T60 (M1 and M15 are not listed due to weak UV absorption); (B) UPLC–UV spectrum of T0; (C) blank UPLC–UV spectrum.
Metabolites 12 00752 g002
Metabolites 12 00752 g003 550
Figure 3. XIC of PF74 in HLMs.
Figure 3. XIC of PF74 in HLMs.
Metabolites 12 00752 g003
Metabolites 12 00752 g004 550
Figure 4. (A) Collision induced dissociation (CID) mass spectrometry of PF74; (B) Analysis of mass spectrometry fragments (m/z 426.2151). Here are major fragment ions (m/z 319.1440, 291.1489, 172.0762, 144.0806, 120.0811) of PF74 without metabolism.
Figure 4. (A) Collision induced dissociation (CID) mass spectrometry of PF74; (B) Analysis of mass spectrometry fragments (m/z 426.2151). Here are major fragment ions (m/z 319.1440, 291.1489, 172.0762, 144.0806, 120.0811) of PF74 without metabolism.
Metabolites 12 00752 g004
Metabolites 12 00752 g005 550
Figure 5. Proposed metabolic pathways of PF74 in HLMs. The main pathways are highlighted in blue.
Figure 5. Proposed metabolic pathways of PF74 in HLMs. The main pathways are highlighted in blue.
Metabolites 12 00752 g005
Metabolites 12 00752 g006 550
Figure 6. UPLC–UV (254–310 nm) chromatograms of 11L in HLMs: (A) UPLC–UV spectrum of T60; (B) UPLC–UV spectrum of T0; (C) blank UPLC–UV spectrum.
Figure 6. UPLC–UV (254–310 nm) chromatograms of 11L in HLMs: (A) UPLC–UV spectrum of T60; (B) UPLC–UV spectrum of T0; (C) blank UPLC–UV spectrum.
Metabolites 12 00752 g006
Metabolites 12 00752 g007 550
Figure 7. XIC of 11L in HLMs.
Figure 7. XIC of 11L in HLMs.
Metabolites 12 00752 g007
Metabolites 12 00752 g008 550
Figure 8. (A) CID mass spectrometry of 11L; (B) analysis of mass spectrometry fragments (positive ion, m/z 580.2224; negative ion, m/z 578.2077). The major fragment ions of 11L without metabolism are positive ions at m/z 443.1384, 296.0697, 268.0749, 138.0914, and negative ions at m/z 441.1228, 311.0818, 294.0552, 254.0602, 156.0116, 92.0495.
Figure 8. (A) CID mass spectrometry of 11L; (B) analysis of mass spectrometry fragments (positive ion, m/z 580.2224; negative ion, m/z 578.2077). The major fragment ions of 11L without metabolism are positive ions at m/z 443.1384, 296.0697, 268.0749, 138.0914, and negative ions at m/z 441.1228, 311.0818, 294.0552, 254.0602, 156.0116, 92.0495.
Metabolites 12 00752 g008
Metabolites 12 00752 g009 550
Figure 9. Proposed metabolic pathways of 11L in HLMs. The main pathways are highlighted in blue.
Figure 9. Proposed metabolic pathways of 11L in HLMs. The main pathways are highlighted in blue.
Metabolites 12 00752 g009
Table
Table 1. List of putative metabolites of PF74 with the primary identification parameters and hypothesized biotransformation. The relatively most intense metabolites are in bold.
Table 1. List of putative metabolites of PF74 with the primary identification parameters and hypothesized biotransformation. The relatively most intense metabolites are in bold.
Metabolite[M + H]+
m/z		Retention Time
(min)		Relative Abundance (UV Peak Area%)UV Peak Area
(254–310 nm)		Type of BiotransformationDiagnostic Ions
M1255.14905.85++Amide hydrolysis (P − C11H9NO)255.15, 120.08
M2460.18666.574.261269Tri-oxidation and demethylation (P + 3O − CH2)460.19, 442.18, 351.13, 323.14, 257.13, 204.07, 190.09, 186.05, 162.05, 120.08
M3460.18666.614.711401Tri-oxidation and demethylation (P + 3O − CH2)460.19, 442.18, 206.08, 204.07, 186.05, 162.05, 136.08
M4 #474.20176.683.541055Tri-oxidation (P + 3O)474.20, 456.19, 222.08, 188.07, 170.06, 152.07, 108.08
M5 *474.20287.054.971480Tri-oxidation (P + 3O)474.20, 456.19, 202.05, 174.06, 120.08, 108.08
M6 *460.18667.052.39713Tri-oxidation and demethylation (P + 3O − CH2)460.19, 442.18, 367.13, 339.13, 222.08, 188.07, 170.06, 152.07
M7444.19177.1113.734088Di-oxidation and demethylation (P + 2O − CH2)444.19, 257.13, 188.07, 170.06, 120.08
M8460.18677.292.67796Tri-oxidation and demethylation (P + 3O − CH2)460.19, 442.18, 202.05, 186.05
M9 *458.20747.4013.484013Di-oxidation(P + 2O)458.21, 440.20, 333.12, 305.13, 204.07, 190.09, 162.05, 108.08
M10 *460.18637.402.87854Tri-oxidation and demethylation (P + 3O − CH2)460.19, 442.20, 351.13, 323.14, 257.13, 204.07, 190.09, 186.05, 162.05, 120.08
M11444.19177.569.812919Di-oxidation and demethylation (P + 2O − CH2)444.19, 204.07, 186.06, 162.05
M12 *460.18647.651.35403Tri-oxidation and demethylation (P + 3O − CH2)460.19, 367.13, 339.13
M13 *444.19187.654.941471Di-oxidation and demethylation (P + 2O − CH2)444.19, 257.13, 188.07, 170.06, 120.08
M14444.19157.7925.627627Di-oxidation and demethylation (P + 2O − CH2)444.19, 204.07, 186.06, 162.05
M15442.21348.75++Mono-oxidation (P + O)442.21, 424.20, 317.13, 289.13, 170.06
M16444.19198.904.291279Di-oxidation and demethylation (P + 2O − CH2)444.19, 204.07, 186.06, 162.06
M17428.19699.371.34399Mono-oxidation and demethylation (P + O − CH2)428.20, 410.19, 317.18, 289.13, 188.07, 170.06
PF74 (Parent)426.21699.91++NA426.22, 319.14, 291.15, 172.08, 144.08, 120.08
The semiquantitative data of UV (254–310 nm) peak area are shown in the table: P, parent; ND, not detected; +, the signal was detected in UPLC–HRMS, but the UV signal was too weak to integrate the peak area at 254–310 nm; #, peak area is the value after deducting blank matrix; *, the metabolite peaks overlapped, and the UV peak area was calculated and allocated according to the ratio of the mass spectrum peak area; NA, not applicable. Relative abundance was calculated by comparing the peak areas of a single metabolite to the sum of the peak areas of all given metabolites. Relative abundance = (peak area of a single metabolite/total peak area of metabolites) × 100%.
Table
Table 2. Accurate quality detection information of PF74 and its metabolites in HLMs.
Table 2. Accurate quality detection information of PF74 and its metabolites in HLMs.
MetaboliteFormulaExact MassMeasured Value
(m/z)		Theoretical Value
(m/z)		PPM
M1C16H18N2O254.1419255.1490255.1492−0.8
M2C26H25N3O5459.1794460.1866460.1867−0.2
M3C26H25N3O5459.1794460.1866460.1867−0.2
M4C27H27N3O5473.1951474.2017474.2024−1.5
M5C27H27N3O5473.1951474.2028474.20240.8
M6C26H25N3O5459.1794460.1866460.1867−0.2
M7C26H25N3O4443.1845444.1917444.1918−0.2
M8C26H25N3O5459.1794460.1867460.18670.0
M9C27H27N3O4457.2002458.2074458.2075−0.2
M10C26H25N3O5459.1794460.1863460.1867−0.9
M11C26H25N3O4443.1845444.1917444.1918−0.2
M12C26H25N3O5459.1794460.1864460.1867−0.7
M13C26H25N3O4443.1845444.1918444.19180.0
M14C26H25N3O4443.1845444.1915444.1918−0.7
M15C27H27N3O3441.2052442.2134442.21252.0
M16C26H25N3O4443.1845444.1919444.19180.2
M17C26H25N3O3427.1896428.1969428.19690.0
PF74C27H27N3O2425.2103426.2169426.2176−1.6
Theoretical value = exact mass + 1.0073 or − 1.0073; PPM = (measured value − theoretical value)/theoretical value × 106.
Table
Table 3. List of putative metabolites of 11L with the primary identification parameters and hypothesized biotransformation. The relatively most intense metabolites are in bold.
Table 3. List of putative metabolites of 11L with the primary identification parameters and hypothesized biotransformation. The relatively most intense metabolites are in bold.
Metabolite[M + H]+/[M − H]−
m/z		Retention Time
(min)		Relative Abundance
(UV Peak Area%)		UV Peak Area
(240–320 nm)		Type of BiotransformationDiagnostic Ions
M1′628.20788.295.367217Tri-oxidation (P + 3O)628.21, 284.07, 138.09
M2′612.21228.495.367223Di-oxidation (P + 2O)612.21, 475.13, 296.07, 268.08, 138.09
M3′582.20148.566.819171 @Mono-oxidation and demethylation (P + O– CH2)582.20, 443.14, 296.07, 268.08, 140.07,
M4′598.19628.600.771043 @Di-oxidation and demethylation (P+ 2O − CH2)598.20, 475.13, 312.07, 172.01, 122.06
M5′552.19178.794.946649N- demethylation and O- demethylation (P − 2CH2)552.19, 443.14, 296.07, 268.08
M6′612.21058.8212.0116,172Di-oxidation (P + 2O)612.21, 475.13, 312.07, 172.01
M7′596.21669.056.628923 @Mono-oxidation (P + O)596.22, 459.13, 296.07, 268.08, 138.09
M8′566.20419.082.253028 @N- demethylation (P − CH2)566.20, 124.08
M9′580.1873 *9.782.593493Mono-oxidation and demethylation (P + O– CH2)580.19, 156.01
M10′580.1874 *9.832.623533Mono-oxidation and demethylation (P + O– CH2)580.19, 156.01
M11′582.20209.988.7711,814Mono-oxidation and demethylation (P + O − CH2)582.20, 172.01, 122.06
M12′594.202110.042.793755Mono-oxidation and dehydrogenation (P + O − 2H)594.20, 254.06, 172.01
M13′610.1976 *10.063.274410Di-oxidation (P + 2O)610.20, 270.06, 172.01
M14′566.206810.293.554777 # @Demethylation (P − CH2)566.20, 443.14, 296.07, 268.08, 156.01
M15′597.200210.3215.9821,520 # @Mono-oxidation and oxidative deamination(P + O − NH + O)597.20, 579.21, 313.05, 285.05
M16′596.215810.369.2012,391 # @Mono-oxidation (P + O)596.22, 312.07, 284.07
11L (Parent)580.2224/578.207710.697.119581NA580.22, 443.14, 415.14, 296.07, 268.08, 240.08 (+);
578.21, 441.12, 311.08, 294.06, 254.06, 228.04, 156.01, 92.05 (−)
The semiquantitative data of UV (240–320 nm) peak area are shown in the table; P, parent; *, the measured values of M9′, M10′, and M13′ (m/z) were obtained using the negative mode data; #, peak area is the value after deducting blank matrix; @, M3′, M4′, M14′–M16′ were separated by cyano columns, M7′ and M8′ were separated by phenyl columns; NA, not applicable. Relative abundance was calculated by comparing the peak areas of a single metabolite to the sum of the peak areas of all given metabolites. Relative abundance = (peak area of a single metabolite/total peak area of metabolites) × 100%.
Table
Table 4. Accurate quality detection information of 11L and its metabolites in HLMs.
Table 4. Accurate quality detection information of 11L and its metabolites in HLMs.
MetaboliteFormulaExact MassMeasured ValueTheoretical ValuePPM
(m/z)(m/z)
M1′C29H33N5O9S627.1999628.2078628.20721.0
M2′C29H33N5O8S611.2050612.2122612.2123−0.2
M3′C28H31N5O7S581.1944582.2014582.2017−0.5
M4′C28H31N5O8S597.1893598.1962598.1966−0.7
M5′C27H29N5O6S551.1839552.1917552.19120.9
M6′C29H33N5O8S611.2050612.2105612.2123−2.9
M7′C29H33N5O7S595.2101596.2166596.2174−1.3
M8′C28H31N5O6S565.1995566.2041566.2068−4.8
M9′C28H31N5O7S581.1944580.1873 *580.18710.3
M10′C28H31N5O7S581.1944580.1874 *580.18710.5
M11′C28H31N5O7S581.1944582.2020582.20170.5
M12′C29H31N5O7S593.1944594.2021594.20170.7
M13′C29H33N5O8S611.2050610.1976 *610.1977−0.2
M14′C28H31N5O6S565.1995566.2068566.20680.0
M15′C29H32N4O8S596.1941597.2002597.2014−2.0
M16′C29H33N5O7S595.2101596.2158596.2174−2.7
11LC29H33N5O6S579.2152580.2224580.2225−0.2
*, The measured values (m/z) of M9′, M10′, and M13′ are based on the data of the negative ion mode. Theoretical value = exact mass + 1.0073 or − 1.0073; PPM = (measured value − theoretical value)/theoretical value × 106.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Xu, S.; Sun, L.; Ding, D.; Zhang, X.; Liu, X.; Zhan, P. Metabolite Identification of HIV-1 Capsid Modulators PF74 and 11L in Human Liver Microsomes. Metabolites 2022, 12, 752. https://doi.org/10.3390/metabo12080752

AMA Style

Xu S, Sun L, Ding D, Zhang X, Liu X, Zhan P. Metabolite Identification of HIV-1 Capsid Modulators PF74 and 11L in Human Liver Microsomes. Metabolites. 2022; 12(8):752. https://doi.org/10.3390/metabo12080752

Chicago/Turabian Style

Xu, Shujing, Lin Sun, Dang Ding, Xujie Zhang, Xinyong Liu, and Peng Zhan. 2022. "Metabolite Identification of HIV-1 Capsid Modulators PF74 and 11L in Human Liver Microsomes" Metabolites 12, no. 8: 752. https://doi.org/10.3390/metabo12080752

APA Style

Xu, S., Sun, L., Ding, D., Zhang, X., Liu, X., & Zhan, P. (2022). Metabolite Identification of HIV-1 Capsid Modulators PF74 and 11L in Human Liver Microsomes. Metabolites, 12(8), 752. https://doi.org/10.3390/metabo12080752

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop